Titre : | Magnesium in the treatment of alcohol withdrawal syndrome: a multicenter randomized controlled trial (2023) |
Auteurs : | G. AIRAGNES ; R. VALTER ; G. DUCOUTUMANY ; C. VANSTEENE ; J. B. TRABUT ; P. GORWOOD ; C. DUBERTRET ; J. MATTA ; A. CHARLES-NELSON ; F. LIMOSIN |
Type de document : | Article : Périodique |
Dans : | Alcohol and Alcoholism (Vol.58, n°3, May 2023) |
Article en page(s) : | 329-335 |
Note générale : |
Comment: Maguire D., McMillan D. Magnesium in the treatment of alcohol withdrawal syndrome: a multicenter randomized controlled trial. Alcohol and Alcoholism, 2023, Vol. 58, n° 5, p. 570. https://doi.org/10.1093/alcalc/agad040
|
Langues: | Anglais |
Discipline : | TRA (Traitement et prise en charge / Treatment and care) |
Mots-clés : |
Thésaurus géographique FRANCEThésaurus mots-clés ETUDE RANDOMISEE ; COMPLEMENTS ALIMENTAIRES ; SEVRAGE ; PHARMACOTHERAPIE ; SYNDROME DE SEVRAGE ; ALCOOL ; BENZODIAZEPINES ; ETUDE CLINIQUE ; EFFICACITE |
Résumé : |
OBJECTIVE: Alcohol withdrawal syndrome (AWS) is a frequent and potentially life-threatening condition experienced in alcohol use disorder. Since hypomagnesemia is involved in AWS's severity, we conducted a multicenter double-blind randomized placebo-controlled trial to examine the efficacy of oral magnesium supplementation as an adjuvant therapy of AWS.
MATERIAL AND METHODS: Inpatients were recruited in six different centers if they had a baseline score higher than eight on the Revised Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar). The experimental treatment was magnesium lactate dehydrate, administrated three times per day providing a total of 426.6 mg per day and up to 15 days. The primary endpoint was the significant between-group difference of the CIWA-Ar total score change from baseline to 3 days later. The treatment group and baseline score were introduced as covariables in an analysis of covariance. RESULTS: A total of 98 inpatients were included {71.4% of men; mean age of 49.1 years [standard deviation (SD): 10.3]}. In the intention-to-treat population, the mean reduction of the CIWA-Ar score in the experimental group between baseline and 3 days later was 10.1 (SD: 5.2), whereas it was 9.2 (SD: 3.9) in the control group. The absolute difference of the adjusted mean in the experimental group compared with the control group was -0.69 (SD: 0.72), which did not correspond to a significant between-group difference (P = 0.34). Per-protocol analysis and sensitivity analyses also supported this result. Supplementary analyses found no significant difference regarding benzodiazepine consumption, magnesium blood concentration, and satisfaction to care. CONCLUSIONS: The present study does not support the rationale of systematic oral magnesium supplementation in patients with AWS. |
Domaine : | Alcool / Alcohol |
Affiliation : | Department of Psychiatry and Addictology, AP-HP, Centre-Université Paris Cité, Paris, France |
Lien : | https://doi.org/10.1093/alcalc/agad021 |
Accueil